Bristol Myers Squibb expanding cell manufacturing in Devens
The building will manufacture lymphoma drug Breyanzi, which the FDA approved earlier this year. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 25, 2021 Category: Biotechnology Authors: Catherine Carlock Source Type: news

Bristol Myers Squibb expanding cell manufacturing in Devens
The building will manufacture lymphoma drug Breyanzi, which the FDA approved earlier this year. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 25, 2021 Category: American Health Authors: Catherine Carlock Source Type: news

Improving immunotherapies for blood cancers: real-time exploration in the tumor
(Institut Pasteur) Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. Some make use of the immune system to act and belong to a class of treatment called " immunotherapies. " But how do these antibodies function within the tumor? And how can we hope to improve their efficacy? Using innovative in vivo imaging approaches, scientists from the Institut Pasteur and Inserm visualized in real time how anti-CD20 antibodies, used to treat B-cell lymphoma, guide the immune system to attack tumor cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 21, 2021 Category: Cancer & Oncology Source Type: news

Penn-developed CAR T therapy shows long-lasting remissions in non-hodgkin lymphoma
(University of Pennsylvania School of Medicine) A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah ™ , researchers in Penn's Abramson Cancer Center reported today in the New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 17, 2021 Category: Cancer & Oncology Source Type: news

Remission of Hodgkin Lymphoma After COVID-19 Remission of Hodgkin Lymphoma After COVID-19
A patient with classic Hodgkin lymphoma seemingly achieved a partial remission following COVID-19.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 16, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Blood-clotting protein plays key role in central nervous system b-cell lymphoma
(Gladstone Institutes) Gladstone researchers have shown in mice that CNS B-cell lymphoma cells cluster at sites where there is a leak in the blood-brain barrier. They also found that a blood protein called fibrinogen, which normally participates in blood clotting, promotes this clustering. Their findings link, for the first time, fibrinogen with CNS B-cell lymphoma, shedding new light on mechanisms of lymphoma growth in the brain that could be further explored as a treatment target. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: news

Novel Index IDs Prognosis in Adults With Burkitt Lymphoma
Validated international prognostic index stratifies patients according to low, intermediate, high risk (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 12, 2021 Category: Cancer & Oncology Tags: Oncology, Pathology, Journal, Source Type: news

Novel Index IDs Prognosis in Adults With Burkitt Lymphoma
FRIDAY, Feb. 12, 2021 -- The Burkitt lymphoma (BL) International Prognostic Index (BL-IPI) provides robust discrimination of survival and can be used for prognostication, according to a study published online Jan. 27 in the Journal of Clinical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 12, 2021 Category: Pharmaceuticals Source Type: news

Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes
Lymphoma patients treated with B-cell-depleting anti-CD20 monoclonal antibodies, such as rituximab or obinutuzumab, may have worse outcomes from COVID-19 infection, according to a study from France.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 9, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study reveals Bayer’s Roundup linked to "a host of chronic and mental illness"
(Natural News) Right now, Bayer is facing a host of lawsuits related to non-Hodgkin’s lymphoma, a type of cancer that has been linked to the use of Roundup herbicide. Bayer took on the legal burdens of Roundup maker Monsanto when it bought the company for $66 billion in 2018. The number of lawsuits related to... (Source: NaturalNews.com)
Source: NaturalNews.com - February 8, 2021 Category: Consumer Health News Source Type: news

Breyanzi Approved for Certain Types of Large B-Cell Lymphoma
MONDAY, Feb. 8, 2021 -- Cell-based gene therapy Breyanzi (lisocabtagene maraleucel) has been approved to treat adults with certain types of large B-cell lymphoma who have not responded to other systemic treatment, the U.S. Food and Drug... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 8, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Umbralisib (Ukoniq) for Two Lymphomas FDA Approves Umbralisib (Ukoniq) for Two Lymphomas
The new drug has been granted an accelerated approval for use in patients with refractory or relapsed marginal zone lymphoma and follicular lymphoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 8, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA OKs New CAR T- Cell Tx for Large B-cell Lymphomas FDA OKs New CAR T- Cell Tx for Large B-cell Lymphomas
Breyanzi is the first agent with an RMAT designation to be licensed by the FDA.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 6, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Breyanzi (lisocabtagene maraleucel) CAR-T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma
PRINCETON, N.J.--(BUSINESS WIRE) February 5, 2021 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 5, 2021 Category: Drugs & Pharmacology Source Type: news

FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 5, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Ukoniq (umbralisib) for Marginal Zone Lymphoma and Follicular Lymphoma
NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has approved Ukoniq™ (umbralisib), for the treatment of adult patients with relapsed or refractory... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 5, 2021 Category: Drugs & Pharmacology Source Type: news

Peninsula diagnostics company Veracyte acquires Decipher Biosciences
Genomic diagnostics company Veracyte is continuing to charge hard into the cancer space with a $600 million cash-and-stock acquisition of San Diego precision oncology company Decipher Biosciences Inc. South San Francisco-based Veracyte (NASDAQ: VCVT) offers a number of genomic diagnostics for indications including lung cancer, breast cancer, thyroid cancer and interstitial lung diseases, along with a forthcoming test for lymphoma. The company's combination with Decipher would add genomic test s… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - February 4, 2021 Category: Health Management Authors: Kevin Truong Source Type: news

What Are the Different Stages of Hodgkin Lymphoma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 3, 2021 Category: General Medicine Source Type: news

Moffitt researchers identify why CAR T therapy may fail in some lymphoma patients
(H. Lee Moffitt Cancer Center& Research Institute) In a new study published in Blood, the official journal of the American Society of Hematology, Moffitt researchers show that immune dysregulation can directly affect the efficacy of CAR T therapy in patients with diffuse large B-cell lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 2, 2021 Category: Cancer & Oncology Source Type: news

Laboratory Workup of Lymphoma in Adults Laboratory Workup of Lymphoma in Adults
This review presents evidence-based guidelines to optimize specimen selection, ancillary diagnostic testing, and appropriate follow-up for safe and accurate diagnosis of lymphoma.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 27, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Cholesterol starvation kills lymphoma cells
(Northwestern University) Scientists have developed a novel therapy to trick cancer cells into gobbling up what they think is their favorite food - cholesterol -- which actually triggers their destruction. What appears to them as a cholesterol-loaded particle is actually a synthetic nanoparticle that binds to the cancer cells and starves them to death. The study was in lymphoma cells but could be effective in ovarian and kidney cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 25, 2021 Category: Cancer & Oncology Source Type: news

Rhizen receives USFDA orphan drug designation for cancer drug
The US Food and Drug Administration (USFDA) has granted orphan drug designation for Tenalisib (RP6530) for the treatment of patients with peripheral T-cell lymphoma (PTCL), Alembic Pharmaceuticals said in a BSE filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 22, 2021 Category: Pharmaceuticals Source Type: news

Expert Alert: What's on the horizon for multiple myeloma and other blood cancers
ROCHESTER, Minnesota -- World Cancer Day is Feb. 4, 2021, highlighting how everyone can help reduce the global burden of cancer. In 2018, there were 17.0 million new cancer cases and 9.5 million cancer deaths worldwide. The three major types of blood cancer are leukemia, lymphoma and myeloma. Multiple myeloma is a cancer that forms [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 20, 2021 Category: Databases & Libraries Source Type: news

What Are the Symptoms of Childhood Lymphoma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 19, 2021 Category: General Medicine Source Type: news

Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
BEDMINSTER, N.J. and SINGAPORE, Jan. 18, 2021 -- (Healthcare Sales & Marketing Network) -- Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, toda... Biopharmaceuticals, Oncology, Regulatory Tessa Therapeutics, CAR-T therapy, Hodgkin Lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 18, 2021 Category: Pharmaceuticals Source Type: news

FDA approves crizotinib for children and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma
Hematology/Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 15, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Pfizer ’s Xalkori (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults
NEW YORK--(BUSINESS WIRE) January 14, 2021 -- Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Xalkori® (crizotinib) for the treatment of pediatric... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 14, 2021 Category: Drugs & Pharmacology Source Type: news

Oncotarget: HIV +/- patients with lymphoma as a predictor of outcome & tumor proliferation
(Impact Journals LLC) The Oncotarget author's hypothesis is that ADC values will inversely correlate with Ki-67 expression and that tumors with higher ADC values above the median will have improved OS and PFS (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2021 Category: International Medicine & Public Health Source Type: news

A potent weapon against lymphomas
(Max Delbr ü ck Center for Molecular Medicine in the Helmholtz Association) MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown inNature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic lymphocytic leukemia, the most common type of blood cancer in adults. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2021 Category: International Medicine & Public Health Source Type: news

Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Myeloid's cell therapy harnesses the innate capabilities of myeloid lineage cells to fight cancer Scientific founders include world-renowned cell therapy & cancer experts Ronald Vale, Ph.D. and Siddhartha Mukherjee, M.D., D.Phil. Co-Founded by Thomas... Biopharmaceuticals, Oncology, Venture Capital Myeloid Therapeutics, lymphoma, glioblastoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 6, 2021 Category: Pharmaceuticals Source Type: news

Is Follicular Lymphoma Deadly
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 5, 2021 Category: General Medicine Source Type: news

Following in the footsteps of Rush Limbaugh, patriot Dan Bongino is sadly poisoning himself with toxic chemotherapy, which destroys lives
(Natural News) Former Secret Service agent and passionate conservative radio host, Dan Bongino, is suffering from Hodgkin lymphoma, a type of blood cancer that begins in the white blood cells of the lymphatic system. The cancer was detected after Bongino spotted a 10-centimeter by 7-centimeter tumor in his neck. After doctors removed the lump, they... (Source: NaturalNews.com)
Source: NaturalNews.com - January 2, 2021 Category: Consumer Health News Source Type: news

Chemotherapy drug may be effective against COVID-19, researchers say
The chemotherapy drug pralatrexate, originally developed to treat lymphoma, may be effective in patients with COVID-19, according to a study published Thursday by the journal PLOS Computational Biology. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 31, 2020 Category: Consumer Health News Source Type: news

First CAR T-cell Tx for Mantle Cell Lymphoma Fills Unmet Need First CAR T-cell Tx for Mantle Cell Lymphoma Fills Unmet Need
Lymphoma specialist Ann LaCasce, MD, comments on brexucabtagene autoleucel, the first FDA-approved CAR T-cell therapy for relapsed or refractory mantle cell lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 31, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New virtual screening strategy identifies existing drug that inhibits COVID-19 virus
A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat COVID-19. Haiping Zhang of the Shenzhen Institutes of Advanced Technology in Shenzhen, China, and colleagues present these findings in the open-access journal PLOS Computational Biology. (Source: World Pharma News)
Source: World Pharma News - December 31, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New virtual screening strategy identifies existing drug that inhibits Covid-19 virus
(PLOS) A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat Covid-19. Haiping Zhang of the Shenzhen Institutes of Advanced Technology in Shenzhen, China, and colleagues present these findings in the open-access journalPLOS Computational Biology. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 31, 2020 Category: Infectious Diseases Source Type: news

Highlights in Mantle Cell Lymphoma From ASH 2020 Highlights in Mantle Cell Lymphoma From ASH 2020
Dr Amanda Cashen from Washington University reviews key studies on mantle cell lymphoma from ASH 2020, including new data on chemotherapy-free frontline options and CAR T-cell therapy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2020 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

Moffitt researchers discover potential new drug target to treat cutaneous T cell lymphoma
(H. Lee Moffitt Cancer Center& Research Institute) In order to improve their understanding of how CTCL develops in hopes of developing new therapies, a team of Moffitt scientists conducted a series of studies. In an article published in The Journal of Clinical Investigation, they demonstrate that decreased expression of the protein SATB1 contributes to CTCL development and that drugs that cause SATB1 to become re-expressed may be potential treatment options for this disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 21, 2020 Category: International Medicine & Public Health Source Type: news

PET useful modality in patients with lymphomas
PET imaging can permit more accurate staging in lymphomas, guide treatment,...Read more on AuntMinnie.comRelated Reading: PET/CT pinpoints Hodgkin's lymphoma treatment response PET rules out need for radiotherapy in lymphoma patients Routine PET field-of-view enough for pediatric lymphoma FDG-PET/CT fails for peripheral T-cell lymphoma outcomes PET obviates toxic chemo for some Hodgkin's patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 16, 2020 Category: Radiology Source Type: news

Potential treatment approach kills lymphoma while sparing healthy cells
(Scripps Research Institute) Scientists at Scripps Research have demonstrated a promising new strategy for treating lymphomas, a group of cancers that begin in infection-fighting cells of the immune system called lymphocytes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 16, 2020 Category: International Medicine & Public Health Source Type: news

Model May Predict Post-treatment Hodgkin Lymphoma Outcomes Model May Predict Post-treatment Hodgkin Lymphoma Outcomes
A model combining interim PET imaging with tumour gene expression profiling may be able to predict post-treatment outcomes in Hodgkin lymphoma patients, say UK researchers in a trial data analysis.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

First Data for CAR T-cell Therapy in Follicular Lymphoma First Data for CAR T-cell Therapy in Follicular Lymphoma
The ZUMA-5 results show impressive responses for patients with refractory/relapsed indolent non-Hodgkin lymphoma, including follicular lymphoma and marginal zone lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Steroids Increase Infection Risk With CAR T-Cell Therapy in NHL Steroids Increase Infection Risk With CAR T-Cell Therapy in NHL
Steroids and multiple prior treatments markedly increase the risk of infection following CAR T-cell therapy in patients with high-grade B-cell non-Hodgkin's lymphoma, UK clinicians have found.Medscape News UK (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

PET imaging tracer proves effective for diagnosing and managing rare CNS B-cell lymphoma
(Society of Nuclear Medicine and Molecular Imaging) Positron emission tomography (PET) imaging with 68Ga-pentixafor is an effective diagnostic tool for central nervous system (CNS) B-cell lymphoma, according to a proof-of-concept study published in the December issue of The Journal of Nuclear Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2020 Category: Cancer & Oncology Source Type: news

ASH: CAR T - Cell Therapy Promising for Relapsed/Refractory iNHL
Phase 2 study reveals high objective response rate for CAR T - cell therapy in patients with follicular lymphoma, marginal zone lymphoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 9, 2020 Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Conference News, Source Type: news

ASH: CAR T-Cell Therapy Promising for Relapsed/Refractory iNHL
WEDNESDAY, Dec. 9, 2020 -- Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, is promising for the treatment of relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 9, 2020 Category: Pharmaceuticals Source Type: news

Allogeneic Transplant: Durable Remissions in T-Cell Lymphomas Allogeneic Transplant: Durable Remissions in T-Cell Lymphomas
Five-year progression-free survival approached 40% and 5-year overall survival was over 50% in the study. Treatment-related mortality ranged from about 8% to 24%, depending on the donor type.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 8, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Duvelisib Response Rate'Exciting' in Patients With r/r PTCL Duvelisib Response Rate'Exciting' in Patients With r/r PTCL
Duvelisib is demonstrating encouraging activity and manageable toxicities among patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) in a phase 2 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 8, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Cancer-hit mum faced with horror treatment choice as she finds out she's pregnant
A CANCER-hit mum has endured what many could never imagine. The mum was told she had Hodgkin's lymphoma, a cancer of the blood, while pregnant with her third child. The harrowing ordeal was not over as she was later told she also had to shield due to coronavirus. (Source: Daily Express - Health)
Source: Daily Express - Health - December 7, 2020 Category: Consumer Health News Source Type: news

New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma
Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained ...
Source: Roche Investor Update - December 7, 2020 Category: Pharmaceuticals Source Type: news